Profile data is unavailable for this security.
About the company
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
- Revenue in EUR (TTM)47.40bn
- Net income in EUR4.22bn
- Incorporated1994
- Employees87.99k
- LocationSanofi SA46 Avenue de la Grande ArmeePARIS 75017FranceFRA
- Phone+33 153774000
- Fax+33 153774463
- Websitehttps://www.sanofi.com/
Mergers & acquisitions
| Acquired company | SAN:PAR since announced | Transaction value |
|---|---|---|
| Mirati Therapeutics Inc | 1.22% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chugai Pharmaceutical Co Ltd | 6.86bn | 2.24bn | 71.69bn | 7.60k | 31.30 | 6.34 | -- | 10.46 | 215.75 | 215.75 | 659.08 | 1,064.55 | 0.5574 | 1.24 | 3.36 | 142,631,400.00 | 18.25 | 19.29 | 21.50 | 23.91 | 69.46 | 63.57 | 32.74 | 28.39 | 4.17 | -- | 0.00 | 40.14 | -11.78 | 13.90 | -13.08 | 28.61 | -0.8947 | 27.23 |
| Merck KGaA | 20.87bn | 2.63bn | 72.17bn | 62.18k | 27.46 | 2.53 | 16.27 | 3.46 | 6.05 | 6.05 | 48.05 | 65.66 | 0.4231 | 1.80 | 4.79 | 331,754.30 | 5.34 | 5.64 | 6.60 | 7.27 | 58.22 | 61.86 | 12.61 | 12.97 | 0.8391 | 59.45 | 0.2729 | 9.26 | -5.57 | 7.19 | -15.09 | 21.40 | 14.77 | 11.97 |
| GSK plc | 37.37bn | 4.79bn | 79.01bn | 70.21k | 16.37 | 4.55 | 9.91 | 2.11 | 0.9796 | 0.9796 | 7.64 | 3.52 | 0.5351 | 1.50 | 4.48 | 447,872.20 | 7.35 | 6.74 | 11.33 | 10.71 | 72.84 | 70.29 | 13.73 | 16.93 | 0.536 | 12.78 | 0.5517 | 79.55 | 3.42 | -0.322 | 15.79 | 7.10 | 5.47 | -10.32 |
| Zoetis Inc | 8.02bn | 2.11bn | 80.06bn | 14.10k | 38.47 | 17.96 | 31.29 | 9.98 | 5.11 | 5.11 | 19.42 | 10.94 | 0.6388 | 1.04 | 6.59 | 632,269.50 | 16.78 | 14.47 | 19.23 | 17.18 | 70.03 | 69.77 | 26.27 | 25.77 | 2.09 | 16.74 | 0.5696 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| CSL Ltd | 13.33bn | 2.38bn | 87.02bn | 30.40k | 36.64 | 5.55 | 26.46 | 6.53 | 8.06 | 8.06 | 45.16 | 53.19 | 0.3986 | 1.25 | 5.80 | 720,758.80 | 7.31 | 9.46 | 8.95 | 11.70 | 51.83 | 53.84 | 18.34 | 20.11 | 0.9705 | 8.74 | 0.3857 | 46.70 | 11.19 | 11.63 | 20.42 | 6.61 | -0.4207 | 7.26 |
| Bristol-Myers Squibb Co | 41.83bn | -5.88bn | 90.70bn | 34.10k | -- | 5.93 | 28.82 | 2.17 | -3.26 | -3.26 | 22.83 | 8.39 | 0.4944 | 4.07 | 4.98 | 1,363,900.00 | -6.94 | 3.05 | -9.03 | 3.76 | 76.18 | 76.13 | -14.04 | 7.69 | 1.02 | 14.60 | 0.7543 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Gilead Sciences, Inc. | 25.01bn | 947.07m | 93.94bn | 18.00k | 102.42 | 5.72 | 27.55 | 3.76 | 0.8191 | 0.8191 | 22.20 | 14.67 | 0.4797 | 3.43 | 6.25 | 1,544,722.00 | 1.78 | 6.74 | 2.26 | 8.12 | 77.44 | 79.14 | 3.71 | 16.95 | 0.9546 | 9.36 | 0.562 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
| Sanofi SA | 47.40bn | 4.22bn | 130.63bn | 87.99k | 30.61 | 1.77 | 20.04 | 2.76 | 3.36 | 3.36 | 37.84 | 58.10 | 0.3716 | 1.43 | 5.64 | 538,639.00 | 3.39 | 5.87 | 4.33 | 7.16 | 68.91 | 68.78 | 9.11 | 16.90 | 0.6484 | 34.81 | 0.2454 | 60.51 | 2.32 | 5.42 | -35.49 | 4.57 | 8.87 | 4.14 |
| Pfizer Inc | 50.04bn | -2.33bn | 151.62bn | 88.00k | -- | 1.92 | 40.78 | 3.03 | -0.4643 | -0.4646 | 9.81 | 15.48 | 0.255 | 1.47 | 5.15 | 632,295.40 | -1.17 | 8.20 | -1.43 | 10.40 | 71.29 | 69.34 | -4.61 | 22.68 | 0.602 | -- | 0.4412 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Amgen Inc | 27.82bn | 2.82bn | 160.89bn | 26.70k | 57.31 | 30.18 | 21.80 | 5.78 | 5.81 | 5.81 | 57.47 | 11.03 | 0.3415 | 1.75 | 4.85 | 1,158,577.00 | 3.46 | 10.36 | 4.39 | 13.06 | 63.30 | 75.41 | 10.12 | 26.51 | 0.8928 | 1.59 | 0.9136 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Sep 2024 | 41.31m | 3.26% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 25.80m | 2.03% |
| Dodge & Coxas of 31 Dec 2023 | 22.51m | 1.78% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 22.06m | 1.74% |
| Amundi Asset Management SA (Investment Management)as of 04 Sep 2024 | 18.78m | 1.48% |
| Geode Capital Management LLCas of 12 Sep 2024 | 14.18m | 1.12% |
| BlackRock Advisors (UK) Ltd.as of 05 Sep 2024 | 13.95m | 1.10% |
| Capital International Ltd.as of 05 Sep 2024 | 13.73m | 1.08% |
| Capital Research & Management Co. (World Investors)as of 05 Sep 2024 | 12.85m | 1.01% |
| FIL Investments Internationalas of 06 Sep 2024 | 10.39m | 0.82% |
